Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 24:14:1132530.
doi: 10.3389/fphar.2023.1132530. eCollection 2023.

Risk factors associated with inappropriate empirical antimicrobial treatment in bloodstream infections. A cohort study

Affiliations

Risk factors associated with inappropriate empirical antimicrobial treatment in bloodstream infections. A cohort study

Beatriz Dietl et al. Front Pharmacol. .

Abstract

Introduction: Bloodstream infections (BSI) are a major cause of mortality all over the world. Inappropriate empirical antimicrobial treatment (i-EAT) impact on mortality has been largely reported. However, information on related factors for the election of i-EAT in the treatment of BSI in adults is lacking. The aim of the study was the identification of risk-factors associated with the use of i-EAT in BSI. Methods: A retrospective, observational cohort study, from a prospective database was conducted in a 400-bed acute-care teaching hospital including all BSI episodes in adult patients between January and December 2018. The main outcome variable was EAT appropriation. Multivariate analysis using logistic regression was performed. Results: 599 BSI episodes were included, 146 (24%) received i-EAT. Male gender, nosocomial and healthcare-associated acquisition of infection, a high Charlson Comorbidity Index (CCI) score and the isolation of multidrug resistant (MDR) microorganisms were more frequent in the i-EAT group. Adequation to local guidelines' recommendations on EAT resulted in 91% of appropriate empirical antimicrobial treatment (a-EAT). Patients receiving i-EAT presented higher mortality rates at day 14 and 30 when compared to patients with a-EAT (14% vs. 6%, p = 0.002 and 22% vs. 9%, p < 0.001 respectively). In the multivariate analysis, a CCI score ≥3 (OR 1.90 (95% CI 1.16-3.12) p = 0.01) and the isolation of a multidrug resistant (MDR) microorganism (OR 3.79 (95% CI 2.28-6.30), p < 0.001) were found as independent risk factors for i-EAT. In contrast, female gender (OR 0.59 (95% CI 0.35-0.98), p = 0.04), a correct identification of clinical syndrome prior to antibiotics administration (OR 0.26 (95% CI 0.16-0.44), p < 0.001) and adherence to local guidelines (OR 0.22 (95% CI 0.13-0.38), p < 0.001) were identified as protective factors against i-EAT. Conclusion: One quarter of BSI episodes received i-EAT. Some of the i-EAT related factors were unmodifiable (male gender, CCI score ≥3 and isolation of a MDR microorganism) but others (incorrect identification of clinical syndrome before starting EAT or the use of local guidelines for EAT) could be addressed to optimize the use of antimicrobials.

Keywords: anti-bacterial agents-therapeutic use; antimicrobial stewardship (ASP) intervention; antimicrobial therapy; bacteremia; bloodstream infections (BSI); risk factors.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Empirical antimicrobial treatment appropriation according to infection source.

References

    1. Abe T., Tokuda Y., Shiraishi A., Fujishima S., Mayumi T., Sugiyama T., et al. (2019). In-hospital mortality associated with the misdiagnosis or unidentified site of infection at admission. Crit. Care 23 (1), 202. 10.1186/s13054-019-2475-9 - DOI - PMC - PubMed
    1. Akaike H. (1992). “Information theory and an extension of the maximum likelihood principle,” in Breakthroughs in statistics: Foundations and basic theory. Editors Kotz S., Johnson N. L. (New York, NY: Springer New York; ), 610–624.
    1. Arias C. A., Murray B. E. (2009). Antibiotic-resistant bugs in the 21st century — a clinical super-challenge. N. Engl. J. Med. 360 (5), 439–443. 10.1056/nejmp0804651 - DOI - PubMed
    1. Bai A. D., Irfan N., Main C., El-Helou P., Mertz D. (2021). Local audit of empiric antibiotic therapy in bacteremia: A retrospective cohort study. PLOS ONE 16 (3), e0248817. 10.1371/journal.pone.0248817 - DOI - PMC - PubMed
    1. Boucher H. W., Talbot G. H., Bradley J. S., Edwards J. E., Gilbert D., Rice L. B., et al. (2009). Bad bugs, no drugs: No ESKAPE! An update from the infectious Diseases society of America. Clin. Infect. Dis. 48 (1), 1–12. 10.1086/595011 - DOI - PubMed

LinkOut - more resources